Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
AKROSOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025, at 10:45 a.m. E.T. in New York, NY.
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
AKROResults support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
AKROPublished results from the 96-Week Phase 2b SYMMETRY trial in
the New England Journal of Medicine
B of A Securities Maintains Buy on Akero Therapeutics, Raises Price Target to $64
AKROWatching Akero Therapeutics; Shares Spike Higher, Traders Circulate Unconfirmed Rumor Of Potential Sale
AKROCitigroup Maintains Buy on Akero Therapeutics, Lowers Price Target to $78
AKROAkero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028
AKROAkero Therapeutics Publishes Results From Phase 2b SYMMETRY Trial In New England Journal of Medicine; Results Support Potential Benefit Of EFX To Elicit Fibrosis Improvement In Patients With F4 Fibrosis
AKROAkero Therapeutics Presents Week 96 Results From Phase 2b SYMMETRY Clinical Trial Of Efruxifermin In Patients With Compensated Cirrhosis Caused By MASH Showing Fibrosis Improvement Without Worsening Of MASH At EASL Congress 2025
AKRO10 Health Care Stocks With Whale Alerts In Today's Session
AKROHC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $75
AKROAkero Therapeutics Said It Has Completed Enrollment In The Double-blind Portion Of The Phase 3 SYNCHRONY Real-world Study Of Efruxifermin (EFX) For Metabolic Dysfunction-Associated Steatohepatits Or Steatotic Liver Disease, Results Expected In 1H Of 2026
AKROCitigroup Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $65
AKROHC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
AKROAkero Therapeutics To Showcase New Analyses Of Phase 2b HARMONY Study In Presentations At 75th Annual AASLD The Liver Meeting 2024
AKROThanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
AKROEvercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck
AKROBerenberg raised the price target for Merck & Co., Inc. (NYSE: MRK) from $95 to $100. Merck shares rose 0.7% to $86.22 in pre-market trading.
Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $30
AKROEvercore ISI Group Upgrades Akero Therapeutics to Outperform, Raises Price Target to $50
AKROImportant Biotech Catalysts For September 13, 2022 - End Of The Day Summary
AKROAkero Therapeutics Announces $175M Proposed Common Stock Offering
AKRODow Drops More Than 1,000 Points, Akero Therapeutics Shares Spike Higher
AKROU.S. stocks traded sharply lower toward the end of trading, following the release of inflation data for August.
Looking Into Akero Therapeutics's Recent Short Interest
AKROAkero Therapeutics's (NASDAQ:AKRO) short percent of float has risen 6.59% since its last report. The company recently reported that it has 6.18 million shares sold short, which is 20.38% of all regular shares that are available for trading.
Nasdaq Tumbles 500 Points, Crude Oil Down Over 1%
AKROU.S. stocks extended losses midway through trading, following the release of inflation data for August
US Stocks Open Lower After Inflation Report, Dow Dips 700 Points
AKROU.S. stocks traded sharply lower this morning, following the release of inflation data for August
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
AKROAkero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study
AKROAkero Therapeutics Announces Phase 2b HARMONY Study Met Primary Endpoints For Both 50mg And 28mg EFX Dose Groups; Study Also Met Key Secondary Endpoint
AKROAkero Therapeutics To Present Results From Phase 2b HARMONY Trial Investigating Efruxifermin In Patients With Pre-Cirrhotic NASH On Sept. 13
AKRO